MTAA Celebrates Partnering with 4D Medical and CathRx to Support Innovative MedTech Development Journey
The Medical Technology Association of Australia (MTAA) is delighted to announce it will be lead partner with both 4D Medical and CathRx to support commercialisation of their new medical technology projects, after they were awarded Australian Government funding through the Clinical Translation and Commercialisation MedTech (CTCM) program – a Medical Research Future Fund (MRFF) initiative delivered by MTPConnect.
In total, six medical technology projects were awarded $6.2 million of funding under Round 2 of the CTCM program, [as announced by the Minister for Health and Aged Care, Hon Mark Butler MP].
4DMedical’s successful application for $1.1 million in CTCM funding will allow the Company to broaden the capability of its XV Scanner beyond ventilation to include the measurement of blood flow (perfusion, Q). This additional capability will strengthen 4DMedical’s position as a leader in non-invasive lung diagnostics by providing detailed quantitative data on respiratory function via a single scan that has many advantages over existing modalities.
In addition, CathRx, with support partner Medical Device Partnering Program (MDPP) at Flinders University, has been awarded CTCM funding of up to $1.5 million with a 1:1 co-contribution from CathRx.
CathRx is an Australian-based medical device company principally involved in the development and manufacture of innovative, low-cost, high-quality electrophysiology catheters for the diagnosis and treatment of cardiac arrhythmias. The technology will help hospitals reduce their economic and environmental costs by allowing reprocessing of the catheters by their on-site central sterilisation departments.
MTAA is also a support partner for the CTCM awarded projects being developed by Ventora Medical and VitalTrace.
MTAA recognises the excellent work of the other CTCM program partners supporting awardees – Cicada Innovations, Medical Device Partnering Program, The BridgeTech Program, and Therapeutic Innovation Australia (agent for the National Collaborative Research Infrastructure Strategy).
MTAA CEO, Ian Burgess, welcomed the announcement. Mr Burgess said MTAA, in conjunction with Cicada Innovations and MDPP, was “looking forward to supporting 4D Medical and CathRx to further their MedTech commercialisation journeys through the challenging clinical trials stage”.
“As the national association representing companies in the medical technology industry in Australia, MTAA is pleased to be one of MTPConnect’s key industry MedTech partners, providing commercialisation support and adding value to the CTCM projects we are partnered with.
“We are also proud of our continued and long-standing relationship with MTPConnect and what it has achieved in the MedTech space with the programs and initiatives it delivers via the MRFF.
“Government funded programs like the CTCM program demonstrate the real benefits of private and public partnerships by recognising the importance of Australian R&D and its contribution to improving human health,” Mr Burgess said.
These projects received MRFF funding from the Australian Government’s Clinical Translation and Commercialisation Medtech program, delivered by MTPConnect.
The importance of start-ups and innovators, like 4D and CathRx, enabling research translation, is highlighted in MTAA’s The Value of MedTech report, a major economic study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and our economy. The report captures the value of research commercialisation, innovation and clinical trials in Australia.
